The data reveal that HER2-positive tumors have a distinct downregulation of proteins in the complement and coagulation cascade while triple-negative and basal-like tumors share enrichment for upregulated proteins related to tRNA biosynthesis, spliceosome, cell cycle, and immune diseases and infections and for downregulated proteins related to extracellular matrix (ECM) receptor interactions. The gene discussed is ERBB2; the disease is immune system disorder.